Melody Counts
Family Medicine · Newport, TNNPI 1811994700
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 139 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Novo Nordisk at 28.6% of the total. Reporting peaked in 2023 at $1,174 and has fallen 88.2% since, to $139 in 2025.
Across 139 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$748
- Medtronic$358
- AbbVie$183
- Pfizer$168
- AstraZeneca$121
- Johnson & Johnson$115
- plus $921 from 19 others
What the payments were for
- Food & beverage$2,600100%
- Entertainment$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 37 | $748 |
| Medtronic | 3 | $358 |
| AbbVie | 13 | $183 |
| Pfizer | 12 | $168 |
| AstraZeneca | 8 | $121 |
| Johnson & Johnson | 7 | $115 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $108 |
| GSK | 7 | $102 |
| E.r. Squibb & Sons, L.L.C. | 6 | $95 |
| Boehringer Ingelheim | 5 | $86 |
| Sumitomo Pharma America, Inc. | 5 | $78 |
| Lilly USA, LLC | 4 | $66 |
| Amgen | 4 | $66 |
| Sunovion Pharmaceuticals Inc. | 5 | $57 |
| Mylan Specialty L.p. | 4 | $55 |
| Merck | 3 | $43 |
| UCB, Inc. | 2 | $34 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $19 |
| Corium, LLC | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Antares Pharma, Inc. | 1 | $14 |
| Novartis | 1 | $14 |
| Optos, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,613 in reported general payments places this provider in the 70th percentile of 2,087 family medicine providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 326 | $10,638 |
| Omeprazole | 35 | $601 |
| Atorvastatin Calcium | 70 | $599 |
| Levothyroxine Sodium | 50 | $434 |
| Fluticasone Propionate | 26 | $402 |
| Tamsulosin Hcl | 16 | $316 |
| Montelukast Sodium | 31 | $276 |
| Glimepiride | 23 | $266 |
| Metoprolol Succinate | 18 | $257 |
| Amlodipine Besylate | 37 | $250 |
| Potassium Chloride | 15 | $226 |
| Rosuvastatin Calcium | 29 | $216 |
| Lisinopril | 38 | $216 |
| Pantoprazole Sodium | 20 | $216 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 11 | $200 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Newport
- Kabir Harricharan SinghNewport$49K
- Catherine SpikerNewport$18K
- Rajkamal Harricharan SinghNewport$17K
- Michael HoodNewport$14K
- Kevin DennisFranklin$354K
- Charolette JacksonBartlett$162K
- Keren HolmesNashville$58K
- Khaisha GistAntioch$49K
- Jerry PunchKnoxville$45K
- Christopher HollowayAntioch$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.